Navegando por Palavras-chave "Immunogenicity"

Agora exibindo 1 - 5 de 5
  • Nenhuma Miniatura disponível
    Item
    Acesso aberto (Open Access)
    Avaliação da virulência e imunogenicidade da espécie emergente Sporothrix brasiliensis
    (Universidade Federal de São Paulo (UNIFESP), 2015-03-12) Della Terra, Paula Portella [UNIFESP]; Camargo, Zoilo Pires de [UNIFESP]; Rodrigues, Anderson Messias [UNIFESP]; http://lattes.cnpq.br/4150370898980718; http://lattes.cnpq.br/0632912481397728; http://lattes.cnpq.br/4948216219562157; Universidade Federal de São Paulo (UNIFESP)
    A esporotricose é uma infecção fúngica crônica granulomatosa subcutânea e polimórfica que afeta homens e animais. O complexo Sporothrix schenckii que agrega os agentes etiológicos causadores desta micose é composto pelas espécies S. brasiliensis, S. schenckii sensu stricto (s. str.), S. globosa e S. luriei. Estes fungos apresentam dimorfismo térmico e alcançam o hospedeiro via inoculação traumática pelo contato com vegetais, solo e animais infectados, entre eles, felinos e tatus. Esta micose apresenta distribuição mundial, com focos endêmicos em países de clima tropical e subtropical. Nas últimas décadas, foram relatados surtos da doença no Brasil por S. brasiliensis intimamente relacionados à transmissão zoonótica por gatos infectados. Este estudo tem como principais objetivos, avaliar o perfil de virulência de isolados representativos de S. brasiliensis, utilizando S. schenckii s. str. e S. globosa como controles. Avaliou-se o perfil de secreção de proteínas/glicoproteínas e a imunogenicidade de tais moléculas. O estudo de patogenicidade foi conduzido através de infecção subcutânea em modelo murino com o intuito de mimetizar a principal rota de infecção. Desta forma, camundongos foram infectados por via subcutânea na pata esquerda com 5x106 leveduras de cada isolado de S. brasiliensis e controles. Os isolados de S. brasiliensis apresentaram diferentes perfis de virulência sendo classificados como pouco, médio e altamente virulento através da análise de carga fúngica presente nos órgãos, perda de peso, indução à morte dos animais infectados. A análise histopatológica revelou lesões teciduais principalmente quando isolados mais virulentos foram inoculados, confirmando a alta capacidade invasiva do S. brasiliensis. Os perfis proteicos dos isolados foram heterogênios. A maioria dos exoantígenos apresentaram proteínas/glicoproteínas de 30 e 35 kDa. Diferentes proteínas dos exoantígenos foram reconhecidas por IgG nos soros de camundongos infectados, sendo a molécula de 70 kDa a mais reconhecida. Os soros dos camundongos infectados com os isolados estudados reconheceram principalmente as moléculas de 100 kDa e 70 kDa presentes no extrato total do isolado Ss54 (S. brasiliensis) e Ss118 (S. schenckii). A caracterização da espécie de relevância epidemiológica no Brasil realizada neste estudo contribuiu para a melhor compreensão da patogênese da esporotricose.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Efeito adjuvante da propionibacterium acnes em vacina de células dendríticas na profilaxia e terapia do melanoma murino
    (Universidade Federal de São Paulo (UNIFESP), 2017-04-25) Ishimura, Mayari Eika [UNIFESP]; Maugeri, Ieda Maria Longo [UNIFESP]; Rodrigues, Elaine Guadelupe [UNIFESP]; http://lattes.cnpq.br/6913514130496062; http://lattes.cnpq.br/0657150642176327; http://lattes.cnpq.br/9202969437650761; Universidade Federal de São Paulo (UNIFESP)
    Hybrid vaccines, which are vaccine models of total antigens expressed by a tumor cell combined with the ability of a dendritic cell (DC) to stimulate immune responses, have been investigated in clinical and experimental studies. However, the response triggered by these vaccines is often weak, requiring the use of adjuvants to increase vaccine immunogenicity. Killed Propionibacterium acnes (P. acnes) exerts immunomodulatory effects by increasing the phagocytic and tumoricidal activities of macrophages, promoting DC maturation, inducing pro-inflammatory cytokines production and increasing the humoral response to different antigens. Here, we evaluated the effect of P. acnes on a specific antitumor immune response elicited by a hybrid vaccine in a C57Bl/6 mouse model of melanoma. Two subcutaneous doses of a hybrid vaccine associated with P. acnes increased total IgG-, IgG1- and IgG2c-specific titers to B16F10 antigens, polarizing the humoral response to a T helper 1 (Th1) pattern. Concerning the cellular immune response, the absolute number of memory CD4 and CD8 T cells was increased. Moreover, cells cultured with tumor antigens exhibited increased IFN-γ secretion and reduced IL-4 expression by CD4 T cells, and CD8 T cells secreted larger amounts of IL-17 and IFN-γ. Furthermore, the addition of P. acnes to a hybrid vaccine increased the cytotoxic activity of splenocytes toward B16F10 in vitro and avoided late tumor progression in a pulmonary colonization model. These results revealed the adjuvant effect of a killed P. acnes suspension, as it improved specific humoral and cellular immune responses elicited by DC-tumor cell hybrid vaccines.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Estudo da imunogenicidade e da segurança da vacina tríplice bacteriana acelular em adolescentes com lupus eritematoso sistêmico juvenil
    (Universidade Federal de São Paulo (UNIFESP), 2018-12-06) Peracchi, Octavio Augusto Bedin [UNIFESP]; Terreri, Maria Teresa de Sande e Lemos Ramos Ascensao [UNIFESP]; Pinto, Maria Isabel de Moraes [UNIFESP]; http://lattes.cnpq.br/0967318191677557; http://lattes.cnpq.br/2661280959330284; http://lattes.cnpq.br/0846892433278057; Universidade Federal de São Paulo (UNIFESP)
    Introduction: The topic immunization in immunosuppressed patients, such as juvenile systemic lupus erythematosus (jSLE), remains highly discussed and it is necessary to protect these individuals against agents to which they are particularly susceptible. Objective: The aim of this study was to evaluate the immunogenicity and safety of the diphtheria, tetanus and acellular pertussis (Tdap) vaccine in adolescents with jSLE and in healthy adolescents. Methods: A prospective longitudinal observational study in which two groups of individuals were evaluated: one of adolescents with jSLE according to Hochberg and SLICC classification criteria (jSLE, n = 26) and a group of healthy adolescents (control, n = 26) compared with the case group by age and sex. A 0.5 ml dose of the diphtheria, tetanus, acellular pertussis (dTpa) vaccine was administered intramuscularly to the non-dominant arm of the selected subjects. Samples of 10 mL of peripheral blood were collected on the day of vaccination (D0) and after 14 days (D14), 28 days (D28), 6 months (D6m) and 12 months (D12m) of the vaccination. Serologies for tetanus, diphtheria and pertussis, immunophenotyping of lymphocytes in peripheral blood and evaluation of cytokines were assessed. The adverse events were assessed in both groups and the disease activity in the jSLE group. Results: There was no difference in the frequency of adverse events between the jSLE group and the control group (p=0.999). When evaluating the disease activity, no difference was found in the mean values of SLEDAI at the D0 to the D28 (p=0.151), D6m (p=0.782) and D12m (p=0.812). No difference was observed in the geometric means of the Tfh cells concentrations per group and at D0 and D14. Both groups showed a significant increase in antibody levels for the three antigens (p<0.001) in D14 and D28. The groups had distinct evolutions for tetanus and pertussis (p=0.004 and p<0.001, respectively). For tetanus and diphtheria, in D14 more than 95% of the patients presented protection and all of them presented in D28. For pertussis, the frequency of seroconversion did not differ in D14 (54%) and D28 (63%), and in D12m this frequency decreased statistically (p=0.004). Patients had significantly lower levels of IFNƔ (p<0.001) and higher IL10 (p=0.001), IL12 (p=0.002), IL21 (p=0.038) and TNFα (p=0.008). Conclusion: Patients with jSLE had a good response to a booster dose with the dTpa vaccine for diphtheria and tetanus antigens, but not for pertussis. This vaccine was shown to be safe in relation to adverse events and absence of reactivation of the disease.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trial
    (Elsevier Sci Ltd, 2017) Safadi, Marco Aurelio P.; Martinon-Torres, Federico; Weckx, Lily Yin [UNIFESP]; Moreira Junior, Edson Duarte; da Fonseca Lima, Eduardo Jorge; Mensi, Ilhem; Calabresi, Marco; Toneatto, Daniela
    Background: After implementation of routine infant MenC vaccination, MenB remains a serious cause of meningococcal disease, yet to be targeted by vaccination programs in several countries. This study (NCT01339923) investigated the immunogenicity and safety of MenC CRM-conjugated vaccine (MenC-CRM) concomitantly administered with MenB vaccine (4CMenB). Methods: Infants (N = 251) were randomised 1:1 to receive 4CMenB and MenC-CRM (Group 1) or MenC-CRM alone (Group 2) at 3 and 5 months (M3, M5) and a booster at 12 months of age (M12), and pneumococcal vaccine at M3, M5, M7, M12. Antibody responses to meningococcal vaccines were measured at M3, M6, M12, and M13. Non-inferiority of MenC-CRM response in Group 1 vs Group 2 was demonstrated at M6 and M13, if the lower limit of the 95% confidence interval (LL95%CI) of the difference in percentage of infants with hSBA titres >= 1:8 was >-10%. Sufficiency of MenB response was achieved if LL95% CI of the percentage of infants with hSBA titres >= 1:4 against fHbp, NadA and PorA strains was >= 70% at M6 or >= 75% at M13. Adverse events (AEs) were collected for 7 days post-vaccination, and serious AEs (SAEs) and medically attended AEs throughout the study. Results: Non-inferiority of MenC response in Group 1 vs Group 2 (LL95%Cl -6.4% [M6]
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil
    (Elsevier B.V., 2012-12-14) Weckx, Lily Yin [UNIFESP]; Thompson, Allison; Berezin, Eitan Naaman; Faria, Sonia Maria de; Cunha, Clovis Arns da; Pride, Michael; Patterson, Scott; Gruber, William C.; Emini, Emilio A.; Scott, Daniel A.; Study Grp 012; Universidade Federal de São Paulo (UNIFESP); Pfizer Inc; Fac Ciencias Med Santa Casa São Paulo; Universidade Federal de Santa Catarina (UFSC); Hosp Infantil Joana de Gusmao; Univ Fed Parana
    Background: the inclusion of 7-valent pneumococcal conjugate vaccine (PCV7) into national immunization programs in many countries has significantly decreased the incidence of disease caused by Streptococcus pneumoniae. However, a substantial portion of disease remained and, in some areas, there has been an increase in disease produced by serotypes not included in PCV7. A 13-valent pneumococcal conjugate vaccine (PCV13) was studied in healthy Brazilian infants in a phase 3, double-blind, randomized study.Methods: Infants were randomized to receive either PCV7 or PCV13 at 2, 4, 6, (doses 1-3), and 12 (toddler dose) months of age, along with routine pediatric vaccinations (diphtheria, tetanus, whole-cell pertussis, and Haemophilus influenzae type b vaccine). Pneumococcal anticapsular polysaccharide-binding immunoglobulin G (IgG) responses and antibody responses to pertussis antigens were measured 1 month after both dose 3 of the infant series and the toddler dose. Safety and tolerability were also assessed.Results: the proportion of subjects achieving a serotype-specific IgG concentration >= 0.35 mu g/mL measured 1 month after the infant series was comparable in the PCV13 (>= 94.2%) and PCV7 (>= 93.0%) groups for the 7 serotypes common to both vaccines. the percentage of responders for the 6 additional serotypes ranged from 87.1 to 100% for PCV13. the percentage of responders varied across the pertussis antigens studied, but was not different in PCV13 and PCV7 recipients. Overall, the safety profile of PCV13 was comparable with that of PCV7.Conclusions: PCV13 was comparable to PCV7 in safety and tolerability, elicited comparable immune responses to the common serotypes, and did not interfere with immune responses to concomitantly administered whole-cell pertussis vaccine. the robust immunogenicity exhibited by PCV13 for the additional serotypes suggests that it could provide significant protection against these serotypes. (C) 2012 Published by Elsevier B.V.